Fortress Biotech, Inc. (FBIO) 10-Year Financial Performance & Capital Metrics

FBIO • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutFortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.Show more

Revenue $58M -31.8%
EBITDA -$106M +22.3%
Net Income -$46M +24.1%
EPS (Diluted) -2.69 +68.2%
Gross Margin 63.8% -12.5%
EBITDA Margin -183.64% -13.8%
Operating Margin -191.38% -13.6%
Net Margin -79.75% -11.2%
ROE -
ROIC -629.42% +75.4%
Debt/Equity -
Interest Coverage -11.12 +2.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 92 (top 8%)
✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Negative free cash flow
✗Shares diluted 100.0% in last year

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y9.5%

3Y-5.71%

TTM-0.32%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM108.22%

EPS CAGR

10Y-

5Y-

3Y-

TTM92.18%

ROCE

10Y Avg-79.97%

5Y Avg-90.1%

3Y Avg-114.79%

Latest-142.02%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	863K	16.48M	187.58M	26.88M	36.63M	45.6M	68.79M	75.74M	84.51M	57.67M
Revenue Growth %	-	18.1%	10.38%	-0.86%	0.36%	0.24%	0.51%	0.1%	0.12%	-0.32%
Cost of Goods Sold+	0	11.35M	161.2M	6.13M	10.53M	14.59M	32.08M	30.77M	22.89M	20.88M
COGS % of Revenue	-	0.69%	0.86%	0.23%	0.29%	0.32%	0.47%	0.41%	0.27%	0.36%
Gross Profit+	863K	5.13M	26.38M	20.76M	26.1M	31M	36.71M	44.97M	61.62M	36.8M
Gross Margin %	1%	0.31%	0.14%	0.77%	0.71%	0.68%	0.53%	0.59%	0.73%	0.64%
Gross Profit Growth %	-	4.95%	4.14%	-0.21%	0.26%	0.19%	0.18%	0.23%	0.37%	-0.4%
Operating Expenses+	51.39M	70.84M	127.59M	140.75M	136.92M	125.28M	225.25M	248.53M	203.96M	147.18M
OpEx % of Revenue	59.55%	4.3%	0.68%	5.24%	3.74%	2.75%	3.27%	3.28%	2.41%	2.55%
Selling, General & Admin	21.58M	32.91M	73.02M	53.37M	55.59M	61.17M	86.84M	113.66M	90.98M	87.73M
SG&A % of Revenue	25.01%	2%	0.39%	1.99%	1.52%	1.34%	1.26%	1.5%	1.08%	1.52%
Research & Development	29.81M	35.13M	52.49M	87.38M	81.33M	64.11M	128.87M	134.88M	106.07M	56.88M
R&D % of Revenue	34.54%	2.13%	0.28%	3.25%	2.22%	1.41%	1.87%	1.78%	1.26%	0.99%
Other Operating Expenses	0	0	-234K	68K	0	0	9.54M	0	6.91M	2.56M
Operating Income+	-50.53M	-65.71M	-89.8M	-120M	-110.82M	-94.27M	-188.54M	-203.56M	-142.34M	-110.38M
Operating Margin %	-58.55%	-3.99%	-0.48%	-4.46%	-3.03%	-2.07%	-2.74%	-2.69%	-1.68%	-1.91%
Operating Income Growth %	-1.45%	-0.3%	-0.37%	-0.34%	0.08%	0.15%	-1%	-0.08%	0.3%	0.22%
EBITDA+	-50.51M	-64.98M	-88.54M	-117.94M	-106.17M	-88.94M	-181.75M	-194.21M	-136.34M	-105.92M
EBITDA Margin %	-58.52%	-3.94%	-0.47%	-4.39%	-2.9%	-1.95%	-2.64%	-2.56%	-1.61%	-1.84%
EBITDA Growth %	-1.45%	-0.29%	-0.36%	-0.33%	0.1%	0.16%	-1.04%	-0.07%	0.3%	0.22%
D&A (Non-Cash Add-back)	26K	728K	1.26M	2.06M	4.65M	5.33M	6.79M	9.35M	6M	4.46M
EBIT	-52.4M	-67.6M	-89.83M	-120.46M	-93.13M	-93.14M	-152.96M	-203.05M	-141.72M	-108.95M
Net Interest Income+	-1.24M	-3.39M	-6.87M	-9.24M	-9.29M	-13.81M	-14.66M	-12.24M	-9.52M	-7.24M
Interest Income	245K	298K	819K	1.1M	2.56M	1.52M	649K	1.4M	3M	2.68M
Interest Expense	1.48M	3.69M	7.69M	10.34M	11.85M	15.33M	15.31M	13.64M	12.52M	9.93M
Other Income/Expense	-3.35M	-5.58M	-7.72M	-10.8M	9.16M	-8.58M	24.19M	-9.9M	-11.29M	-10.16M
Pretax Income+	-53.88M	-71.29M	-98.32M	-130.8M	-101.66M	-102.85M	-164.35M	-213.46M	-153.63M	-120.54M
Pretax Margin %	-62.44%	-4.33%	-0.52%	-4.87%	-2.78%	-2.26%	-2.39%	-2.82%	-1.82%	-2.09%
Income Tax+	0	0	1.51M	-463K	0	136K	473K	449K	521K	312K
Effective Tax Rate %	0.9%	0.77%	0.68%	0.64%	0.39%	0.45%	0.39%	0.41%	0.39%	0.38%
Net Income+	-48.43M	-55.09M	-66.88M	-84.15M	-39.96M	-46.53M	-64.7M	-86.58M	-60.64M	-46M
Net Margin %	-56.12%	-3.34%	-0.36%	-3.13%	-1.09%	-1.02%	-0.94%	-1.14%	-0.72%	-0.8%
Net Income Growth %	-1.38%	-0.14%	-0.21%	-0.26%	0.53%	-0.16%	-0.39%	-0.34%	0.3%	0.24%
Net Income (Continuing)	-53.88M	-71.29M	-97.51M	-130.8M	-101.66M	-102.98M	-164.83M	-213.91M	-154.15M	-120.86M
Discontinued Operations	0	0	0	-11.14M	0	0	0	0	0	0
Minority Interest	27.43M	44.47M	67.93M	17.89M	46.32M	96.66M	117.2M	8.3M	-20.96M	-24.38M
EPS (Diluted)+	-18.56	-20.68	-24.08	-29.04	-10.95	-9.75	-11.85	-14.55	-8.47	-2.69
EPS Growth %	-1.2%	-0.11%	-0.16%	-0.21%	0.62%	0.11%	-0.22%	-0.23%	0.42%	0.68%
EPS (Basic)	-18.56	-20.68	-24.08	-29.04	-10.95	-9.75	-11.85	-14.55	-8.47	-2.69
Diluted Shares Outstanding	2.61M	2.66M	2.78M	2.9M	3.65M	4.8M	5.45M	5.92M	8.11M	20.78M
Basic Shares Outstanding	2.61M	2.66M	2.78M	2.9M	3.65M	4.8M	5.45M	5.92M	8.11M	20.78M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	99.78M	109.63M	183.18M	111.21M	156.25M	266.15M	346.46M	230.43M	117.02M	90.37M
Cash & Short-Term Investments	98.18M	91.68M	130.95M	83.11M	136.86M	233.35M	305.74M	178.27M	80.93M	57.26M
Cash Only	98.18M	88.29M	113.92M	65.51M	136.86M	233.35M	305.74M	178.27M	80.93M	57.26M
Short-Term Investments	0	3.39M	39.03M	17.6M	0	0	0	0	0	0
Accounts Receivable	0	5.19M	15.15M	5.5M	14.4M	24.67M	23.79M	28.35M	15.39M	10.4M
Days Sales Outstanding	-	114.88	29.48	74.65	143.53	197.49	126.23	136.6	66.46	65.83
Inventory	0	203K	171K	678K	857K	1.4M	9.86M	14.16M	10.21M	14.43M
Days Inventory Outstanding	-	6.53	0.39	40.4	29.7	35.11	112.19	167.93	162.72	252.28
Other Current Assets	1.6M	0	38.57M	15.18M	0	6.72M	0	9.66M	10.5M	8.28M
Total Non-Current Assets+	18.83M	61.1M	62.77M	29.79M	70.17M	67.26M	50.04M	63.87M	50.5M	53.85M
Property, Plant & Equipment	309K	7.38M	9.51M	12.02M	33.91M	32.41M	34.07M	33.01M	23.5M	17.12M
Fixed Asset Turnover	2.79x	2.23x	19.72x	2.24x	1.08x	1.41x	2.02x	2.29x	3.60x	3.37x
Goodwill	0	18.64M	18.64M	0	0	0	0	0	0	0
Intangible Assets	1.25M	17.41M	15.22M	1.42M	7.38M	14.63M	12.55M	27.2M	20.29M	31.86M
Long-Term Investments	2.48M	1.41M	1.39M	0	11.15M	19.21M	2.22M	2.69M	2.44M	1.55M
Other Non-Current Assets	14.79M	16.25M	18M	16.35M	17.73M	1.01M	3.42M	3.66M	4.28M	3.32M
Total Assets+	118.61M	170.73M	245.95M	140.99M	226.42M	333.41M	396.5M	294.3M	167.53M	144.22M
Asset Turnover	0.01x	0.10x	0.76x	0.19x	0.16x	0.14x	0.17x	0.26x	0.50x	0.40x
Asset Growth %	0.33%	0.44%	0.44%	-0.43%	0.61%	0.47%	0.19%	-0.26%	-0.43%	-0.14%
Total Current Liabilities+	10.58M	56.56M	71.44M	55.61M	45.62M	51.76M	101.04M	127.72M	84.91M	71.4M
Accounts Payable	1.87M	14.21M	10M	17.86M	10.05M	11.41M	47.43M	57.24M	34.81M	31.64M
Days Payables Outstanding	-	457.11	22.65	1.06K	348.37	285.42	539.57	678.93	555	553.05
Short-Term Debt	0	2.03M	13.23M	19.08M	7.22M	6.37M	5.32M	10.18M	9.45M	625K
Deferred Revenue (Current)	0	0	0	0	0	0	1000K	728K	0	0
Other Current Liabilities	6.22M	24.54M	42.14M	1.29M	27K	27.14M	34.42M	46.62M	31.27M	4.84M
Current Ratio	9.43x	1.94x	2.56x	2.00x	3.43x	5.14x	3.43x	1.80x	1.38x	1.27x
Quick Ratio	9.43x	1.93x	2.56x	1.99x	3.41x	5.11x	3.33x	1.69x	1.26x	1.06x
Cash Conversion Cycle	-	-335.7	7.22	-949.02	-175.13	-52.81	-301.15	-374.4	-325.82	-234.94
Total Non-Current Liabilities+	23.76M	31.2M	54.01M	65.64M	108.27M	84.65M	69.58M	116.56M	81.03M	74.47M
Long-Term Debt	23.17M	26.18M	49.27M	60.42M	82.43M	59.81M	46.56M	93.14M	60.86M	57.96M
Capital Lease Obligations	0	0	0	0	23.71M	22.89M	20.99M	21.57M	18.28M	14.75M
Deferred Tax Liabilities	-493K	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	584K	5.01M	4.74M	5.21M	2.14M	1.95M	2.03M	1.85M	1.89M	1.76M
Total Liabilities	34.34M	87.76M	125.45M	121.25M	153.89M	136.41M	170.63M	244.28M	165.94M	145.87M
Total Debt+	23.17M	28.21M	62.5M	79.5M	115.14M	89.08M	74.98M	127.34M	88.59M	75.96M
Net Debt	-75.01M	-60.08M	-47.41M	13.99M	-21.72M	-144.28M	-230.77M	-50.92M	7.67M	18.7M
Debt / Equity	0.27x	0.34x	0.52x	4.03x	1.59x	0.45x	0.33x	2.55x	55.82x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-34.05x	-17.81x	-11.68x	-11.61x	-9.35x	-6.15x	-12.32x	-14.92x	-11.37x	-11.12x
Total Equity+	84.27M	82.97M	120.5M	19.74M	72.53M	197M	225.88M	50.02M	1.59M	-1.64M
Equity Growth %	0.19%	-0.02%	0.45%	-0.84%	2.67%	1.72%	0.15%	-0.78%	-0.97%	-2.04%
Book Value per Share	32.29	31.14	43.39	6.81	19.89	41.04	41.47	8.44	0.20	-0.08
Total Shareholders' Equity	56.85M	38.49M	52.57M	1.85M	26.21M	100.34M	108.67M	41.72M	22.54M	22.74M
Common Stock	47K	49K	551K	717K	574K	95K	101K	110K	15K	28K
Retained Earnings	-190.16M	-245.25M	-312.13M	-396.27M	-436.23M	-482.76M	-547.46M	-634.23M	-694.87M	-740.87M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-68K	-481K	0	0	0	0	0	0	0	0
Minority Interest	27.43M	44.47M	67.93M	17.89M	46.32M	96.66M	117.2M	8.3M	-20.96M	-24.38M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-20.38M	-45.81M	-85.43M	-98.85M	-94.96M	-83.68M	-116.54M	-179.4M	-128.22M	-80.19M
Operating CF Margin %	-23.61%	-2.78%	-0.46%	-3.68%	-2.59%	-1.84%	-1.69%	-2.37%	-1.52%	-1.39%
Operating CF Growth %	-0.25%	-1.25%	-0.86%	-0.16%	0.04%	0.12%	-0.39%	-0.54%	0.29%	0.37%
Net Income	-53.88M	-71.29M	-99.84M	-130.8M	-101.66M	-102.98M	-164.83M	-213.91M	-154.15M	-120.86M
Depreciation & Amortization	26K	1.13M	3.35M	2.06M	4.65M	5.33M	6.79M	9.35M	6M	4.46M
Stock-Based Compensation	14.29M	12.13M	14.01M	15.01M	13.19M	13.45M	19.49M	22.99M	17.03M	32.62M
Deferred Taxes	2.11M	-73K	-8.56M	287K	0	0	0	0	0	0
Other Non-Cash Items	11.89M	10.32M	7.84M	8.86M	-6.3M	5.31M	-14.36M	2.89M	15.42M	11.71M
Working Capital Changes	5.19M	1.97M	-2.23M	5.74M	-4.84M	-4.78M	36.37M	-715K	-12.52M	-8.13M
Change in Receivables	0	-1.83M	-5.93M	2.26M	-6.91M	-10.32M	834K	-4.84M	12.52M	4.47M
Change in Inventory	0	-203K	32K	-507K	-179K	-547K	-8.46M	1.74M	3.95M	-4.22M
Change in Payables	5.89M	5.39M	9.9M	4.66M	1.95M	11.1M	43.31M	8.35M	-24.38M	-6.39M
Cash from Investing+	7.88M	-6.06M	-41.63M	18.82M	20.1M	-7.16M	40.51M	-22.93M	-2.1M	-15M
Capital Expenditures	-11.98M	-6.37M	-5.45M	-9.36M	-2.35M	-1.93M	-4.57M	-2.71M	-63K	-15M
CapEx % of Revenue	13.88%	0.39%	0.03%	0.35%	0.06%	0.04%	0.07%	0.04%	0%	0.26%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	11.56M	-4.14M	-163K	7.51M	6.04M	-5.24M	-11.78M	-213K	-2.04M	0
Cash from Financing+	60.92M	42.91M	150.38M	50.65M	146.71M	172.41M	148.99M	75.32M	32.74M	70.64M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	-299K	-2.34M	-2.56M	-6.75M	-8.78M	-8.78M	-8.77M	-4.71M
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-855K	-594K	-6.6M	-2.73M	-9.96M	-8.78M	-4.8M	-6.74M	-529K	-163K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-32.36M	-56.32M	-90.88M	-108.2M	-104.36M	-90.85M	-132.89M	-182.46M	-136.32M	-95.19M
FCF Margin %	-37.5%	-3.42%	-0.48%	-4.03%	-2.85%	-1.99%	-1.93%	-2.41%	-1.61%	-1.65%
FCF Growth %	-0.98%	-0.74%	-0.61%	-0.19%	0.04%	0.13%	-0.46%	-0.37%	0.25%	0.3%
FCF per Share	-12.40	-21.14	-32.72	-37.35	-28.61	-18.93	-24.40	-30.79	-16.81	-4.58
FCF Conversion (FCF/Net Income)	0.42x	0.83x	1.28x	1.17x	2.38x	1.80x	1.80x	2.07x	2.11x	1.74x
Interest Paid	0	400K	778K	0	5.9M	8.82M	6.92M	9.42M	7.95M	7.16M
Taxes Paid	0	104K	4.24M	0	0	0	993K	858K	0	120K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-62.57%	-65.89%	-65.74%	-120%	-86.61%	-34.52%	-30.6%	-62.76%	-234.97%	-
Return on Invested Capital (ROIC)	-172.12%	-306.54%	-146.45%	-175.05%	-196.59%	-136.57%	-591.24%	-	-2555.51%	-629.42%
Gross Margin	100%	31.13%	14.06%	77.22%	71.25%	67.99%	53.36%	59.37%	72.91%	63.8%
Net Margin	-5611.59%	-334.31%	-35.65%	-313.02%	-109.09%	-102.03%	-94.06%	-114.3%	-71.75%	-79.75%
Debt / Equity	0.27x	0.34x	0.52x	4.03x	1.59x	0.45x	0.33x	2.55x	55.82x	-
Interest Coverage	-34.05x	-17.81x	-11.68x	-11.61x	-9.35x	-6.15x	-12.32x	-14.92x	-11.37x	-11.12x
FCF Conversion	0.42x	0.83x	1.28x	1.17x	2.38x	1.80x	1.80x	2.07x	2.11x	1.74x
Revenue Growth	-	1809.62%	1038.25%	-85.67%	36.26%	24.49%	50.86%	10.11%	11.58%	-31.76%

Revenue by Segment

	2016	2017	2018	2019	2020	2021	2022	2023	2024
Qbrexza	-	-	-	-	-	17.06M	26.71M	25.41M	25.11M
Qbrexza Growth	-	-	-	-	-	-	56.63%	-4.88%	-1.16%
Accutane	-	-	-	-	-	10.05M	18.37M	20.17M	19.41M
Accutane Growth	-	-	-	-	-	-	82.76%	9.77%	-3.77%
Amzeeq	-	-	-	-	-	-	7.24M	6.2M	5.01M
Amzeeq Growth	-	-	-	-	-	-	-	-14.37%	-19.22%
Zilxi	-	-	-	-	-	-	2.27M	1.96M	1.64M
Zilxi Growth	-	-	-	-	-	-	-	-13.68%	-16.26%
Targadox	-	-	21.23M	28.07M	-	22.38M	7.97M	3.2M	-
Targadox Growth	-	-	-	32.24%	-	-	-64.38%	-59.81%	-
Exelderm	-	-	-	-	-	5.36M	3.46M	2.4M	-
Exelderm Growth	-	-	-	-	-	-	-35.43%	-30.84%	-
Ximino	-	-	-	3.6M	-	8.25M	4.96M	287K	-
Ximino Growth	-	-	-	-	-	-	-39.89%	-94.21%	-
Other Branded Revenue	-	-	2.15M	6.85M	-	37K	-	-	-
Other Branded Revenue Growth	-	-	-	218.60%	-	-	-	-	-
Dermatology Products Sales	3.59M	15.52M	-	-	44.53M	-	-	-	-
Dermatology Products Sales Growth	-	332.67%	-	-	-	-	-	-	-
Pharmaceutical And Biotechnology Product Development	2.57M	1.73M	-	-	1.07M	-	-	-	-
Pharmaceutical And Biotechnology Product Development Growth	-	-32.88%	-	-	-	-	-	-	-
Return Reserve	-	-	2.4M	2.9M	-	-	-	-	-
Return Reserve Growth	-	-	-	20.83%	-	-	-	-	-
License And Service	-	-	-	1.7M	-	-	-	-	-
License And Service Growth	-	-	-	-	-	-	-	-	-
Royalty	-	-	400K	100K	-	-	-	-	-
Royalty Growth	-	-	-	-75.00%	-	-	-	-	-
License and Service	-	-	3.6M	-	-	-	-	-	-
License and Service Growth	-	-	-	-	-	-	-	-	-
Financial Service Activities	10.32M	170.34M	-	-	-	-	-	-	-
Financial Service Activities Growth	-	1550.09%	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Fortress Biotech, Inc. (FBIO) reported $62.3M in revenue for fiscal year 2024.

Fortress Biotech, Inc. (FBIO) saw revenue decline by 31.8% over the past year.

Yes, Fortress Biotech, Inc. (FBIO) is profitable, generating $4.0M in net income for fiscal year 2024 (-79.8% net margin).

Dividend & Returns

Yes, Fortress Biotech, Inc. (FBIO) pays a dividend with a yield of 0.96%. This makes it attractive for income-focused investors.

Fortress Biotech, Inc. (FBIO) had negative free cash flow of $66.1M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Fortress Biotech, Inc. (FBIO) 10-Year Financial Performance & Capital Metrics

FBIO • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $58M -31.8%
EBITDA -$106M +22.3%
Net Income -$46M +24.1%
EPS (Diluted) -2.69 +68.2%
Gross Margin 63.8% -12.5%
EBITDA Margin -183.64% -13.8%
Operating Margin -191.38% -13.6%
Net Margin -79.75% -11.2%
ROE -
ROIC -629.42% +75.4%
Debt/Equity -
Interest Coverage -11.12 +2.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 92 (top 8%)
✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Negative free cash flow
✗Shares diluted 100.0% in last year

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y9.5%

3Y-5.71%

TTM-0.32%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM108.22%

EPS CAGR

10Y-

5Y-

3Y-

TTM92.18%

ROCE

10Y Avg-79.97%

5Y Avg-90.1%

3Y Avg-114.79%

Latest-142.02%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	863K	16.48M	187.58M	26.88M	36.63M	45.6M	68.79M	75.74M	84.51M	57.67M
Revenue Growth %	-	18.1%	10.38%	-0.86%	0.36%	0.24%	0.51%	0.1%	0.12%	-0.32%
Cost of Goods Sold+	0	11.35M	161.2M	6.13M	10.53M	14.59M	32.08M	30.77M	22.89M	20.88M
COGS % of Revenue	-	0.69%	0.86%	0.23%	0.29%	0.32%	0.47%	0.41%	0.27%	0.36%
Gross Profit+	863K	5.13M	26.38M	20.76M	26.1M	31M	36.71M	44.97M	61.62M	36.8M
Gross Margin %	1%	0.31%	0.14%	0.77%	0.71%	0.68%	0.53%	0.59%	0.73%	0.64%
Gross Profit Growth %	-	4.95%	4.14%	-0.21%	0.26%	0.19%	0.18%	0.23%	0.37%	-0.4%
Operating Expenses+	51.39M	70.84M	127.59M	140.75M	136.92M	125.28M	225.25M	248.53M	203.96M	147.18M
OpEx % of Revenue	59.55%	4.3%	0.68%	5.24%	3.74%	2.75%	3.27%	3.28%	2.41%	2.55%
Selling, General & Admin	21.58M	32.91M	73.02M	53.37M	55.59M	61.17M	86.84M	113.66M	90.98M	87.73M
SG&A % of Revenue	25.01%	2%	0.39%	1.99%	1.52%	1.34%	1.26%	1.5%	1.08%	1.52%
Research & Development	29.81M	35.13M	52.49M	87.38M	81.33M	64.11M	128.87M	134.88M	106.07M	56.88M
R&D % of Revenue	34.54%	2.13%	0.28%	3.25%	2.22%	1.41%	1.87%	1.78%	1.26%	0.99%
Other Operating Expenses	0	0	-234K	68K	0	0	9.54M	0	6.91M	2.56M
Operating Income+	-50.53M	-65.71M	-89.8M	-120M	-110.82M	-94.27M	-188.54M	-203.56M	-142.34M	-110.38M
Operating Margin %	-58.55%	-3.99%	-0.48%	-4.46%	-3.03%	-2.07%	-2.74%	-2.69%	-1.68%	-1.91%
Operating Income Growth %	-1.45%	-0.3%	-0.37%	-0.34%	0.08%	0.15%	-1%	-0.08%	0.3%	0.22%
EBITDA+	-50.51M	-64.98M	-88.54M	-117.94M	-106.17M	-88.94M	-181.75M	-194.21M	-136.34M	-105.92M
EBITDA Margin %	-58.52%	-3.94%	-0.47%	-4.39%	-2.9%	-1.95%	-2.64%	-2.56%	-1.61%	-1.84%
EBITDA Growth %	-1.45%	-0.29%	-0.36%	-0.33%	0.1%	0.16%	-1.04%	-0.07%	0.3%	0.22%
D&A (Non-Cash Add-back)	26K	728K	1.26M	2.06M	4.65M	5.33M	6.79M	9.35M	6M	4.46M
EBIT	-52.4M	-67.6M	-89.83M	-120.46M	-93.13M	-93.14M	-152.96M	-203.05M	-141.72M	-108.95M
Net Interest Income+	-1.24M	-3.39M	-6.87M	-9.24M	-9.29M	-13.81M	-14.66M	-12.24M	-9.52M	-7.24M
Interest Income	245K	298K	819K	1.1M	2.56M	1.52M	649K	1.4M	3M	2.68M
Interest Expense	1.48M	3.69M	7.69M	10.34M	11.85M	15.33M	15.31M	13.64M	12.52M	9.93M
Other Income/Expense	-3.35M	-5.58M	-7.72M	-10.8M	9.16M	-8.58M	24.19M	-9.9M	-11.29M	-10.16M
Pretax Income+	-53.88M	-71.29M	-98.32M	-130.8M	-101.66M	-102.85M	-164.35M	-213.46M	-153.63M	-120.54M
Pretax Margin %	-62.44%	-4.33%	-0.52%	-4.87%	-2.78%	-2.26%	-2.39%	-2.82%	-1.82%	-2.09%
Income Tax+	0	0	1.51M	-463K	0	136K	473K	449K	521K	312K
Effective Tax Rate %	0.9%	0.77%	0.68%	0.64%	0.39%	0.45%	0.39%	0.41%	0.39%	0.38%
Net Income+	-48.43M	-55.09M	-66.88M	-84.15M	-39.96M	-46.53M	-64.7M	-86.58M	-60.64M	-46M
Net Margin %	-56.12%	-3.34%	-0.36%	-3.13%	-1.09%	-1.02%	-0.94%	-1.14%	-0.72%	-0.8%
Net Income Growth %	-1.38%	-0.14%	-0.21%	-0.26%	0.53%	-0.16%	-0.39%	-0.34%	0.3%	0.24%
Net Income (Continuing)	-53.88M	-71.29M	-97.51M	-130.8M	-101.66M	-102.98M	-164.83M	-213.91M	-154.15M	-120.86M
Discontinued Operations	0	0	0	-11.14M	0	0	0	0	0	0
Minority Interest	27.43M	44.47M	67.93M	17.89M	46.32M	96.66M	117.2M	8.3M	-20.96M	-24.38M
EPS (Diluted)+	-18.56	-20.68	-24.08	-29.04	-10.95	-9.75	-11.85	-14.55	-8.47	-2.69
EPS Growth %	-1.2%	-0.11%	-0.16%	-0.21%	0.62%	0.11%	-0.22%	-0.23%	0.42%	0.68%
EPS (Basic)	-18.56	-20.68	-24.08	-29.04	-10.95	-9.75	-11.85	-14.55	-8.47	-2.69
Diluted Shares Outstanding	2.61M	2.66M	2.78M	2.9M	3.65M	4.8M	5.45M	5.92M	8.11M	20.78M
Basic Shares Outstanding	2.61M	2.66M	2.78M	2.9M	3.65M	4.8M	5.45M	5.92M	8.11M	20.78M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	99.78M	109.63M	183.18M	111.21M	156.25M	266.15M	346.46M	230.43M	117.02M	90.37M
Cash & Short-Term Investments	98.18M	91.68M	130.95M	83.11M	136.86M	233.35M	305.74M	178.27M	80.93M	57.26M
Cash Only	98.18M	88.29M	113.92M	65.51M	136.86M	233.35M	305.74M	178.27M	80.93M	57.26M
Short-Term Investments	0	3.39M	39.03M	17.6M	0	0	0	0	0	0
Accounts Receivable	0	5.19M	15.15M	5.5M	14.4M	24.67M	23.79M	28.35M	15.39M	10.4M
Days Sales Outstanding	-	114.88	29.48	74.65	143.53	197.49	126.23	136.6	66.46	65.83
Inventory	0	203K	171K	678K	857K	1.4M	9.86M	14.16M	10.21M	14.43M
Days Inventory Outstanding	-	6.53	0.39	40.4	29.7	35.11	112.19	167.93	162.72	252.28
Other Current Assets	1.6M	0	38.57M	15.18M	0	6.72M	0	9.66M	10.5M	8.28M
Total Non-Current Assets+	18.83M	61.1M	62.77M	29.79M	70.17M	67.26M	50.04M	63.87M	50.5M	53.85M
Property, Plant & Equipment	309K	7.38M	9.51M	12.02M	33.91M	32.41M	34.07M	33.01M	23.5M	17.12M
Fixed Asset Turnover	2.79x	2.23x	19.72x	2.24x	1.08x	1.41x	2.02x	2.29x	3.60x	3.37x
Goodwill	0	18.64M	18.64M	0	0	0	0	0	0	0
Intangible Assets	1.25M	17.41M	15.22M	1.42M	7.38M	14.63M	12.55M	27.2M	20.29M	31.86M
Long-Term Investments	2.48M	1.41M	1.39M	0	11.15M	19.21M	2.22M	2.69M	2.44M	1.55M
Other Non-Current Assets	14.79M	16.25M	18M	16.35M	17.73M	1.01M	3.42M	3.66M	4.28M	3.32M
Total Assets+	118.61M	170.73M	245.95M	140.99M	226.42M	333.41M	396.5M	294.3M	167.53M	144.22M
Asset Turnover	0.01x	0.10x	0.76x	0.19x	0.16x	0.14x	0.17x	0.26x	0.50x	0.40x
Asset Growth %	0.33%	0.44%	0.44%	-0.43%	0.61%	0.47%	0.19%	-0.26%	-0.43%	-0.14%
Total Current Liabilities+	10.58M	56.56M	71.44M	55.61M	45.62M	51.76M	101.04M	127.72M	84.91M	71.4M
Accounts Payable	1.87M	14.21M	10M	17.86M	10.05M	11.41M	47.43M	57.24M	34.81M	31.64M
Days Payables Outstanding	-	457.11	22.65	1.06K	348.37	285.42	539.57	678.93	555	553.05
Short-Term Debt	0	2.03M	13.23M	19.08M	7.22M	6.37M	5.32M	10.18M	9.45M	625K
Deferred Revenue (Current)	0	0	0	0	0	0	1000K	728K	0	0
Other Current Liabilities	6.22M	24.54M	42.14M	1.29M	27K	27.14M	34.42M	46.62M	31.27M	4.84M
Current Ratio	9.43x	1.94x	2.56x	2.00x	3.43x	5.14x	3.43x	1.80x	1.38x	1.27x
Quick Ratio	9.43x	1.93x	2.56x	1.99x	3.41x	5.11x	3.33x	1.69x	1.26x	1.06x
Cash Conversion Cycle	-	-335.7	7.22	-949.02	-175.13	-52.81	-301.15	-374.4	-325.82	-234.94
Total Non-Current Liabilities+	23.76M	31.2M	54.01M	65.64M	108.27M	84.65M	69.58M	116.56M	81.03M	74.47M
Long-Term Debt	23.17M	26.18M	49.27M	60.42M	82.43M	59.81M	46.56M	93.14M	60.86M	57.96M
Capital Lease Obligations	0	0	0	0	23.71M	22.89M	20.99M	21.57M	18.28M	14.75M
Deferred Tax Liabilities	-493K	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	584K	5.01M	4.74M	5.21M	2.14M	1.95M	2.03M	1.85M	1.89M	1.76M
Total Liabilities	34.34M	87.76M	125.45M	121.25M	153.89M	136.41M	170.63M	244.28M	165.94M	145.87M
Total Debt+	23.17M	28.21M	62.5M	79.5M	115.14M	89.08M	74.98M	127.34M	88.59M	75.96M
Net Debt	-75.01M	-60.08M	-47.41M	13.99M	-21.72M	-144.28M	-230.77M	-50.92M	7.67M	18.7M
Debt / Equity	0.27x	0.34x	0.52x	4.03x	1.59x	0.45x	0.33x	2.55x	55.82x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-34.05x	-17.81x	-11.68x	-11.61x	-9.35x	-6.15x	-12.32x	-14.92x	-11.37x	-11.12x
Total Equity+	84.27M	82.97M	120.5M	19.74M	72.53M	197M	225.88M	50.02M	1.59M	-1.64M
Equity Growth %	0.19%	-0.02%	0.45%	-0.84%	2.67%	1.72%	0.15%	-0.78%	-0.97%	-2.04%
Book Value per Share	32.29	31.14	43.39	6.81	19.89	41.04	41.47	8.44	0.20	-0.08
Total Shareholders' Equity	56.85M	38.49M	52.57M	1.85M	26.21M	100.34M	108.67M	41.72M	22.54M	22.74M
Common Stock	47K	49K	551K	717K	574K	95K	101K	110K	15K	28K
Retained Earnings	-190.16M	-245.25M	-312.13M	-396.27M	-436.23M	-482.76M	-547.46M	-634.23M	-694.87M	-740.87M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-68K	-481K	0	0	0	0	0	0	0	0
Minority Interest	27.43M	44.47M	67.93M	17.89M	46.32M	96.66M	117.2M	8.3M	-20.96M	-24.38M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-20.38M	-45.81M	-85.43M	-98.85M	-94.96M	-83.68M	-116.54M	-179.4M	-128.22M	-80.19M
Operating CF Margin %	-23.61%	-2.78%	-0.46%	-3.68%	-2.59%	-1.84%	-1.69%	-2.37%	-1.52%	-1.39%
Operating CF Growth %	-0.25%	-1.25%	-0.86%	-0.16%	0.04%	0.12%	-0.39%	-0.54%	0.29%	0.37%
Net Income	-53.88M	-71.29M	-99.84M	-130.8M	-101.66M	-102.98M	-164.83M	-213.91M	-154.15M	-120.86M
Depreciation & Amortization	26K	1.13M	3.35M	2.06M	4.65M	5.33M	6.79M	9.35M	6M	4.46M
Stock-Based Compensation	14.29M	12.13M	14.01M	15.01M	13.19M	13.45M	19.49M	22.99M	17.03M	32.62M
Deferred Taxes	2.11M	-73K	-8.56M	287K	0	0	0	0	0	0
Other Non-Cash Items	11.89M	10.32M	7.84M	8.86M	-6.3M	5.31M	-14.36M	2.89M	15.42M	11.71M
Working Capital Changes	5.19M	1.97M	-2.23M	5.74M	-4.84M	-4.78M	36.37M	-715K	-12.52M	-8.13M
Change in Receivables	0	-1.83M	-5.93M	2.26M	-6.91M	-10.32M	834K	-4.84M	12.52M	4.47M
Change in Inventory	0	-203K	32K	-507K	-179K	-547K	-8.46M	1.74M	3.95M	-4.22M
Change in Payables	5.89M	5.39M	9.9M	4.66M	1.95M	11.1M	43.31M	8.35M	-24.38M	-6.39M
Cash from Investing+	7.88M	-6.06M	-41.63M	18.82M	20.1M	-7.16M	40.51M	-22.93M	-2.1M	-15M
Capital Expenditures	-11.98M	-6.37M	-5.45M	-9.36M	-2.35M	-1.93M	-4.57M	-2.71M	-63K	-15M
CapEx % of Revenue	13.88%	0.39%	0.03%	0.35%	0.06%	0.04%	0.07%	0.04%	0%	0.26%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	11.56M	-4.14M	-163K	7.51M	6.04M	-5.24M	-11.78M	-213K	-2.04M	0
Cash from Financing+	60.92M	42.91M	150.38M	50.65M	146.71M	172.41M	148.99M	75.32M	32.74M	70.64M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	-299K	-2.34M	-2.56M	-6.75M	-8.78M	-8.78M	-8.77M	-4.71M
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-855K	-594K	-6.6M	-2.73M	-9.96M	-8.78M	-4.8M	-6.74M	-529K	-163K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-32.36M	-56.32M	-90.88M	-108.2M	-104.36M	-90.85M	-132.89M	-182.46M	-136.32M	-95.19M
FCF Margin %	-37.5%	-3.42%	-0.48%	-4.03%	-2.85%	-1.99%	-1.93%	-2.41%	-1.61%	-1.65%
FCF Growth %	-0.98%	-0.74%	-0.61%	-0.19%	0.04%	0.13%	-0.46%	-0.37%	0.25%	0.3%
FCF per Share	-12.40	-21.14	-32.72	-37.35	-28.61	-18.93	-24.40	-30.79	-16.81	-4.58
FCF Conversion (FCF/Net Income)	0.42x	0.83x	1.28x	1.17x	2.38x	1.80x	1.80x	2.07x	2.11x	1.74x
Interest Paid	0	400K	778K	0	5.9M	8.82M	6.92M	9.42M	7.95M	7.16M
Taxes Paid	0	104K	4.24M	0	0	0	993K	858K	0	120K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-62.57%	-65.89%	-65.74%	-120%	-86.61%	-34.52%	-30.6%	-62.76%	-234.97%	-
Return on Invested Capital (ROIC)	-172.12%	-306.54%	-146.45%	-175.05%	-196.59%	-136.57%	-591.24%	-	-2555.51%	-629.42%
Gross Margin	100%	31.13%	14.06%	77.22%	71.25%	67.99%	53.36%	59.37%	72.91%	63.8%
Net Margin	-5611.59%	-334.31%	-35.65%	-313.02%	-109.09%	-102.03%	-94.06%	-114.3%	-71.75%	-79.75%
Debt / Equity	0.27x	0.34x	0.52x	4.03x	1.59x	0.45x	0.33x	2.55x	55.82x	-
Interest Coverage	-34.05x	-17.81x	-11.68x	-11.61x	-9.35x	-6.15x	-12.32x	-14.92x	-11.37x	-11.12x
FCF Conversion	0.42x	0.83x	1.28x	1.17x	2.38x	1.80x	1.80x	2.07x	2.11x	1.74x
Revenue Growth	-	1809.62%	1038.25%	-85.67%	36.26%	24.49%	50.86%	10.11%	11.58%	-31.76%

Revenue by Segment

	2016	2017	2018	2019	2020	2021	2022	2023	2024
Qbrexza	-	-	-	-	-	17.06M	26.71M	25.41M	25.11M
Qbrexza Growth	-	-	-	-	-	-	56.63%	-4.88%	-1.16%
Accutane	-	-	-	-	-	10.05M	18.37M	20.17M	19.41M
Accutane Growth	-	-	-	-	-	-	82.76%	9.77%	-3.77%
Amzeeq	-	-	-	-	-	-	7.24M	6.2M	5.01M
Amzeeq Growth	-	-	-	-	-	-	-	-14.37%	-19.22%
Zilxi	-	-	-	-	-	-	2.27M	1.96M	1.64M
Zilxi Growth	-	-	-	-	-	-	-	-13.68%	-16.26%
Targadox	-	-	21.23M	28.07M	-	22.38M	7.97M	3.2M	-
Targadox Growth	-	-	-	32.24%	-	-	-64.38%	-59.81%	-
Exelderm	-	-	-	-	-	5.36M	3.46M	2.4M	-
Exelderm Growth	-	-	-	-	-	-	-35.43%	-30.84%	-
Ximino	-	-	-	3.6M	-	8.25M	4.96M	287K	-
Ximino Growth	-	-	-	-	-	-	-39.89%	-94.21%	-
Other Branded Revenue	-	-	2.15M	6.85M	-	37K	-	-	-
Other Branded Revenue Growth	-	-	-	218.60%	-	-	-	-	-
Dermatology Products Sales	3.59M	15.52M	-	-	44.53M	-	-	-	-
Dermatology Products Sales Growth	-	332.67%	-	-	-	-	-	-	-
Pharmaceutical And Biotechnology Product Development	2.57M	1.73M	-	-	1.07M	-	-	-	-
Pharmaceutical And Biotechnology Product Development Growth	-	-32.88%	-	-	-	-	-	-	-
Return Reserve	-	-	2.4M	2.9M	-	-	-	-	-
Return Reserve Growth	-	-	-	20.83%	-	-	-	-	-
License And Service	-	-	-	1.7M	-	-	-	-	-
License And Service Growth	-	-	-	-	-	-	-	-	-
Royalty	-	-	400K	100K	-	-	-	-	-
Royalty Growth	-	-	-	-75.00%	-	-	-	-	-
License and Service	-	-	3.6M	-	-	-	-	-	-
License and Service Growth	-	-	-	-	-	-	-	-	-
Financial Service Activities	10.32M	170.34M	-	-	-	-	-	-	-
Financial Service Activities Growth	-	1550.09%	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Fortress Biotech, Inc. (FBIO) reported $62.3M in revenue for fiscal year 2024.

Fortress Biotech, Inc. (FBIO) saw revenue decline by 31.8% over the past year.

Yes, Fortress Biotech, Inc. (FBIO) is profitable, generating $4.0M in net income for fiscal year 2024 (-79.8% net margin).

Dividend & Returns

Yes, Fortress Biotech, Inc. (FBIO) pays a dividend with a yield of 0.96%. This makes it attractive for income-focused investors.

Fortress Biotech, Inc. (FBIO) had negative free cash flow of $66.1M in fiscal year 2024, likely due to heavy capital investments.